Company: DAWN
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0001140361-25-013462
Chunk: 42

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 42
---
 or that may be deemed to be beneficially owned, by BlackRock, certain of its subsidiaries and affiliates, and other companies. The business address and principal executive offices of BlackRock, Inc. is 50 Hudson Yards, New York, NY 10001. |

29

TABLE OF CONTENTS

EXECUTIVE OFFICERS The names of our executive officers, their ages as of the date of this Proxy Statement and their positions are shown below:

| Name                         |     | Age |     | Position(s)                                             |
| Jeremy Bender, Ph.D., M.B.A. |     |  53 |     | Chief Executive Officer, President and Director         |
| Charles York II, M.B.A.      |     |  48 |     | Chief Operating Officer, Chief Financial Officer        |
| Adam Dubow                   |     |  58 |     | General Counsel, Chief Compliance Officer and Secretary |
| Lauren Merendino(1)          |     |  50 |     | Chief Commercial Officer                                |

| (1) | Lauren Merendino has served as our Chief Commercial Officer since June 2023. In February 2025, she was appointed as “officer” within the meaning of Section 16 of, and Rule 16a 1(f) of the rules promulgated under, the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, and “executive officers” of the Company within the meaning of Item 401(b) of Regulation S K, Rule 405 promulgated under the Securities Act of 1933, as amended, and Rule 3b-7 promulgated under the Exchange Act. |

Our board of directors chooses executive officers, who then serve at the discretion of our board of directors. There is no family relationship between any of the directors or executive officers and any of our other directors or executive officers. For information regarding Dr. Bender, please refer to “Proposal No. 1 Election of Directors.” Charles York joined Day One in 2021. He has over 20 years of experience in corporate finance in public and private enterprises in transactional and strategic capital formation roles, notably, operations, corporate and business development in the biotechnology industry. Previously, Mr. York served as Chief Financial Officer and Head of Corporate Development of Aeglea Biotherapeutics, a biotechnology company specializing in rare metabolic disease, where he led capital formation and allocation, investor relations, and corporate development since September 2015, after